Brokerages Set Microbot Medical Inc. (NASDAQ:MBOT) Target Price at $8.75

Microbot Medical Inc. (NASDAQ:MBOT) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.50.

A number of equities analysts recently weighed in on MBOT shares. B. Riley Financial started coverage on shares of Microbot Medical in a research report on Tuesday. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Microbot Medical in a research note on Friday, November 28th. Wall Street Zen lowered shares of Microbot Medical from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th. Roth Mkm started coverage on shares of Microbot Medical in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price objective for the company. Finally, B. Riley Securities started coverage on Microbot Medical in a report on Tuesday. They issued a “buy” rating and a $5.00 price objective on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MBOT. Cornerstone Advisory LLC acquired a new stake in Microbot Medical in the third quarter valued at $30,000. Zacks Investment Management purchased a new position in shares of Microbot Medical in the 3rd quarter valued at about $33,000. Squarepoint Ops LLC acquired a new stake in shares of Microbot Medical in the third quarter valued at about $37,000. Foundations Investment Advisors LLC acquired a new stake in shares of Microbot Medical in the third quarter valued at about $38,000. Finally, SLT Holdings LLC purchased a new stake in Microbot Medical during the third quarter worth about $38,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

Microbot Medical Stock Up 4.5%

Shares of MBOT stock opened at $2.09 on Tuesday. The stock’s 50-day moving average price is $2.07 and its 200 day moving average price is $2.60. The stock has a market capitalization of $140.36 million, a PE ratio of -4.64 and a beta of 1.28. Microbot Medical has a 52-week low of $1.25 and a 52-week high of $4.67.

Microbot Medical (NASDAQ:MBOT) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Analysts expect that Microbot Medical will post -0.71 earnings per share for the current fiscal year.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.